Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 313Carcinoma, Non-Small-Cell Lung 265Neoplasms 253Prostatic Neoplasms 217Colorectal Neoplasms 192Multiple Myeloma 147Lung Neoplasms 147Neoplasm Metastasis 138Ovarian Neoplasms 133Leukemia, Myeloid, Acute 120Pancreatic Neoplasms 111Melanoma 99Squamous Cell Carcinoma of Head and Neck 94Recurrence 88Endometrial Neoplasms 85Lymphoma, Non-Hodgkin 79Carcinoma, Renal Cell 79Stomach Neoplasms 72Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Lymphoma 72Glioblastoma 71Carcinoma, Hepatocellular 71Brain Neoplasms 71Uterine Cervical Neoplasms 67Triple Negative Breast Neoplasms 65Glioma 64Head and Neck Neoplasms 63Leukemia, Lymphocytic, Chronic, B-Cell 62Sarcoma 60Urinary Bladder Neoplasms 57

Interventions

mirdametinib 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Primary Malignant Peripheral Nerve Sheath Tumors × 30 days × Clear all
NCT06693284 2026-05-29

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

University of Minnesota

Phase EARLY_PHASE1 Recruiting
8 enrolled

Primary Malignant Peripheral Nerve Sheath Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡